Cargando…

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN

BACKGROUND: We assessed the safety profile of lasmiditan, a selective 5-HT(1F) receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine. METHODS: SAMURAI and SPARTAN were Phase 3 double-blind studies of patients with migraine, randomized to oral lasmiditan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krege, John H, Rizzoli, Paul B, Liffick, Emily, Doty, Erin G, Dowsett, Sherie A, Wang, Jianing, Buchanan, Andrew S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787764/ https://www.ncbi.nlm.nih.gov/pubmed/31166697 http://dx.doi.org/10.1177/0333102419855080

Ejemplares similares

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)
por: Loo, Li Shen, et al.
Publicado: (2019)

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
por: Loo, Li Shen, et al.
Publicado: (2019)

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021)

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study
por: Ashina, Messoud, et al.
Publicado: (2021)

A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN
por: Lipton, Richard B., et al.
Publicado: (2021)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
por: Smith, Timothy, et al.
Publicado: (2020)

Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
por: Doty, Erin Gautier, et al.
Publicado: (2019)

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study
por: Wilbraham, Darren, et al.
Publicado: (2019)

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks
por: Tepper, Stewart J., et al.
Publicado: (2020)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
por: Blumenfeld, Andrew, et al.
Publicado: (2023)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
por: Lipton, Richard B., et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
por: Doty, Erin G., et al.
Publicado: (2022)

The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings
por: Tepper, Stewart J., et al.
Publicado: (2019)

Lasmiditan: A New Promising Drug in Migraine
por: Prakash, Sanjay, et al.
Publicado: (2021)

Samurai
por: Matsubara, Hisako
Publicado: (1997)

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
por: Brandes, Jan Lewis, et al.
Publicado: (2019)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

The Agile Samurai
por: Rasmusson, Jonathan
Publicado: (2010)

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies
por: Ashina, Messoud, et al.
Publicado: (2019)

Phylarchus and the Spartan revolution
por: Africa, Thomas W.
Publicado: (1961)

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
por: Kuca, Bernice, et al.
Publicado: (2018)

Budget impact of lasmiditan for the acute treatment of migraine in the United States
por: Milev, Sandra, et al.
Publicado: (2021)

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
por: Shapiro, Robert E., et al.
Publicado: (2019)

El último samurái /
por: DeWitt, Helen, 1957-
Publicado: (2018)

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
por: Goadsby, Peter J, et al.
Publicado: (2019)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018)

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
por: Anderson, Christopher C, et al.
Publicado: (2023)

Los siete samurais (videograbación)
Publicado: (1990)

Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Duloxetine and Pregnancy Outcomes: Safety Surveillance Findings
por: Hoog, Sharon L, et al.
Publicado: (2013)

Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial
por: Takeshima, Takao, et al.
Publicado: (2022)

Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
por: Kudrow, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_24guhtjlojel0qus7k2ja7fm62